MedCap Valuation
Is MCAPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MCAPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MCAPS (SEK272) is trading above our estimate of fair value (SEK20.07)
Significantly Below Fair Value: MCAPS is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MCAPS?
Key metric: As MCAPS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is MCAPS's PE Ratio? | |
|---|---|
| PE Ratio | 30.2x |
| Earnings | SEK 122.80m |
| Market Cap | SEK 3.71b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.1x |
| Enterprise Value/EBITDA | 20x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does MCAPS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.6x | ||
HVO hVIVO | 8.4x | -15.2% | UK£146.3m |
ERGO Ergomed | 46.7x | 14.2% | UK£701.1m |
C4XD C4X Discovery Holdings | 2.9x | -88.3% | UK£30.3m |
BVXP Bioventix | 24.3x | n/a | UK£197.0m |
MCAPS MedCap | 30.2x | n/a | SEK 3.7b |
Price-To-Earnings vs Peers: MCAPS is good value based on its Price-To-Earnings Ratio (30.2x) compared to the peer average (53.8x).
Price to Earnings Ratio vs Industry
How does MCAPS's PE Ratio compare vs other companies in the European Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: MCAPS is good value based on its Price-To-Earnings Ratio (30.2x) compared to the European Life Sciences industry average (39x).
Price to Earnings Ratio vs Fair Ratio
What is MCAPS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 30.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MCAPS's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Regeneron Pharmaceuticals
US$81.2b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$753.98
7D
0.6%
1Y
-8.0%
Formycon
€882.8m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€50.00
7D
7.5%
1Y
-24.1%
hVIVO
UK£146.3m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.21
7D
-6.1%
1Y
3.4%